Hemispherx links with SA biotech Bioclones on cancer vaccine

USA-based Hemispherx Biopharma (NYSE MKT: HEB) has entered a strategic alliance to develop multiple projects with Bioclones, a leading South African biotechnology company.

On June 25, Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principle goals:

1) initiating studies utilizing Ampligen (rintatolimod) as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine, currently in clinical trials in Cape Town, including preclinical studies followed, potentially, by a Phase I clinical trial;